| 发明名称 |
formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica. |
| 摘要 |
Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels. |
| 申请公布号 |
BRPI1009392(A2) |
申请公布日期 |
2016.03.08 |
| 申请号 |
BR2010PI09392 |
申请日期 |
2010.03.10 |
| 申请人 |
NORDIC BIOSCIENCE A/S |
发明人 |
CLAUS CHRISTIANSEN;MORTEN ASSER KARSDAL |
| 分类号 |
A61K9/00;A61K38/23;A61P3/10;A61P5/50 |
主分类号 |
A61K9/00 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
